The Ameliorative Effect of Naltrexone/Bupropion, Liraglutide and Caloric Restriction on Blood Pressure Changes in Diabetic Male Albino Rats | ||
| Fayoum University Medical Journal | ||
| Volume 15, Issue 2, June 2025, Pages 97-111 PDF (1013.55 K) | ||
| Document Type: Full Length research Papers | ||
| DOI: 10.21608/fumj.2025.332201.1415 | ||
| Authors | ||
| Reem Ahmed Hammad* 1; Amani M. El Amin2; Ahmed M. El Ebiary2; Dina H. Merzeban1 | ||
| 1Department of Medical Physiology, Faculty of Medicine, Fayoum University, Fayoum, Egypt. | ||
| 2Department of Medical Physiology, Faculty of Medicine, Fayoum University, Fayoum, Egypt | ||
| Abstract | ||
| Introduction: Diabetes significantly increases the risk of cardiovascular diseases and death. Using medical interventions to treat diabetes in order to prevent or minimize negative impacts on the cardiovascular system. Aim of work: To assess the effects of Naltrexone/Bupropion, Liraglutide, and caloric restriction on cardiovascular outcomes in diabetic male albino rats. Methodology: This research involves a comparison of 50 male albino rats divided into 5 groups; group I: a normal control group, group II a: a diabetic control group, group II b: a caloric-restricted group, group II c: (NTX+BUP) treated group (1 NTX / 10 BUP, orally) and group II d: liraglutide treated group (0.3mg/kg/day, S.C). SBP, DBP, MAP, fasting glucose, serum insulin level, and measurements were taken of the lipid profile, and calculations were performed for atherogenic indices such as atherogenic index of plasma, Castelli’s risk index I and II, and atherogenic coefficient. Results: The findings showed a notable enhancement in end SBP in every intervention group in comparison to the obese diabetic control group (P<0.05). In terms of the ultimate MAP, there was a notable reduction in both the caloric-restricted group and the liraglutide group. Conclusion: Our study highlights the potential benefits of (NTX+BUP), and liraglutide in blood pressure reduction and improving atherogenic indices suggesting using them as a potential therapeutic approach in hypertensive diabetic patients. Keywords: Naltrexone/Bupropion, Liraglutide, Caloric restriction, Type 2 diabetes, Rats. | ||
| Keywords | ||
| Naltrexone/Bupropion; Liraglutide; Caloric restriction; Type 2 diabetes; Rats | ||
|
Statistics Article View: 96 PDF Download: 59 |
||
